Important questions for the malignant hematologist to consider when designing or evaluating a study with patient‐reported outcome measures (PROMs). (29th April 2022)

• Record Type: Journal Article
• Authors: Balitsky, Amaris K.; D'Souza, Anita; Levine, Mark N.
• Is Part Of: European journal of haematology. Volume 109:Number 1(2022)
• Page Start: 3
• Page End: 9
• Publication Date: 2022-04-29
• Subjects: clinical research -- malignant haematology -- patient‐reported outcome measures; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13774
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Patient‐reported outcome measures (PROMs), which are measures of symptom burden, health‐related quality of life (HRQoL), and therapy effectiveness have become increasingly important in clinical research. They are unique in that they are reported directly from the patient, without clinician interpretation, thereby avoiding clinician bias. With an increased focus on the patient at the center of health care, PROMs have been increasingly incorporated into clinical research, systematic reviews, and clinical guidelines. Despite the recognition of the importance of including PROMs into clinical haematologic cancer research, barriers have prevented their integration into cancer research. This review highlights the value of including PROMs into clinical haematologic cancer research and addresses the methodological challenges in using and evaluating PROMs. We propose important questions for the malignant haematologist to consider when designing or evaluating a study that includes PROMs.